HR
ZYNE

Howe & Rusling’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Howe & Rusling’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-165
Closed -$1K – 904
2019
Q4 		$1K Hold
165
– – ﹤0.01% 807
2019
Q3 		$1K Hold
165
– – ﹤0.01% 813
2019
Q2 		$2K Buy
+165
New +$1.91K ﹤0.01% 697

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Howe & Rusling's ZYNE Position: Q1 2020 in Review

Howe & Rusling sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2020, closing a stake of 165 shares — an estimated $1K sold.

Howe & Rusling first reported a position in ZYNE in Q2 2019 and held it in 3 quarters. The position peaked at $2K in Q2 2019. 77 funds tracked by Wall St. Rank hold ZYNE as of Q1 2020.

  • Howe & Rusling reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2020 after selling out during the quarter.
  • Howe & Rusling sold 165 Zynerba Pharmaceuticals, Inc shares in Q1 2020, an estimated $1K.
  • Howe & Rusling first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 3 quarters.
  • Howe & Rusling's Zynerba Pharmaceuticals, Inc position peaked at $2K in Q2 2019.
  • 77 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2020.

Based on Howe & Rusling's 13F filing for Q1 2020, filed 14 May 2020.